| Year |
Citation |
Score |
| 2022 |
Craner M, Al Malik Y, Babtain FA, Alshamrani F, Alkhawajah MM, Alfugham N, Al-Yafeai RH, Aljarallah S, Makkawi S, Qureshi S, Ziehn M, Wahba H. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab. Neurology and Therapy. PMID 36048334 DOI: 10.1007/s40120-022-00401-4 |
0.358 |
|
| 2022 |
Mao-Draayer Y, Cohen JA, Bar-Or A, Han MH, Singer B, Williams IM, Meng X, Elam C, Weiss JL, Cox GM, Ziehn M, Cree BA. Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 8: 20552173221115023. PMID 35936922 DOI: 10.1177/20552173221115023 |
0.383 |
|
| 2022 |
Burtchell J, Clemmons D, Clemmons J, Sabutis T, Rosenberg A, Graves J, Sweeney ML, Kramer J, Ziehn M, Brown B, Weiss JL, Obeidat AZ. A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies. Neurology and Therapy. PMID 35608740 DOI: 10.1007/s40120-022-00349-5 |
0.383 |
|
| 2021 |
Galetta K, Deshpande C, Healy BC, Glanz B, Ziehn M, Saxena S, Paul A, Saleh F, Collins M, Gaitan-Walsh P, Castro-Mendoza P, Weiner HL, Chitnis T. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology. PMID 33492760 DOI: 10.1002/acn3.51305 |
0.339 |
|
| 2012 |
Ziehn MO, Avedisian AA, Dervin SM, Umeda EA, O'Dell TJ, Voskuhl RR. Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 12312-24. PMID 22956822 DOI: 10.1523/Jneurosci.2796-12.2012 |
0.639 |
|
| 2012 |
Gold SM, Sasidhar MV, Lagishetty V, Spence RD, Umeda E, Ziehn MO, Krieger T, Schulz KH, Heesen C, Hewison M, Voskuhl RR. Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation. The Journal of Clinical Endocrinology and Metabolism. 97: E1402-10. PMID 22659246 DOI: 10.1210/Jc.2012-1294 |
0.466 |
|
| 2012 |
Ziehn MO, Avedisian AA, Dervin SM, O'Dell TJ, Voskuhl RR. Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Laboratory Investigation; a Journal of Technical Methods and Pathology. 92: 1234-45. PMID 22525427 DOI: 10.1038/Labinvest.2012.76 |
0.615 |
|
| 2010 |
Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Laboratory Investigation; a Journal of Technical Methods and Pathology. 90: 774-86. PMID 20157291 DOI: 10.1038/Labinvest.2010.6 |
0.626 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2019 |
Fox EJ, Lublin FD, Wolinsky JS, Cohen JA, Williams IM, Meng X, Ziehn M, Kolodny S, Cree BAC. Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS. Neurology(R) Neuroimmunology & Neuroinflammation. 6. PMID 31511330 DOI: 10.1212/NXI.0000000000000614 |
0.241 |
|
| 2022 |
Torres JB, Roodselaar J, Sealey M, Ziehn M, Bigaud M, Kneuer R, Leppert D, Weckbecker G, Cornelissen B, Anthony DC. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Frontiers in Immunology. 13: 814064. PMID 35967378 DOI: 10.3389/fimmu.2022.814064 |
0.232 |
|
| 2020 |
Nicholas J, Halpern R, Ziehn M, Peterson-Brandt J, Leszko M, Deshpande C. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States. Journal of Medical Economics. 1-9. PMID 32338098 DOI: 10.1080/13696998.2020.1761821 |
0.149 |
|
| Hide low-probability matches. |